First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
May 11, 2021 08:00 ET
|
Adaptimmune Therapeutics plc
- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC...
Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
April 27, 2021 16:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical...
Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021
April 22, 2021 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 22, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
February 25, 2021 07:30 ET
|
Adaptimmune Therapeutics plc
- Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers - - Reported compelling durable responses in patients with synovial sarcoma,...
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
November 20, 2020 07:30 ET
|
Adaptimmune Therapeutics plc
- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma - - Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for...
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
November 19, 2020 09:00 ET
|
Adaptimmune Therapeutics plc
- Data support confidence in SPEARHEAD-1 as a registrational trial - - Projected to complete recruitment of all patients in Q1 2021 - - Median duration of response was 28 weeks with ongoing...
Adaptimmune to Host Virtual Investor Day on Friday, November 20th
November 12, 2020 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor...
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
November 09, 2020 15:18 ET
|
Adaptimmune Therapeutics plc
- Data support continued development of ADP-A2M4CD8 - - On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 - PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020...
Adaptimmune Reports Q3 Financial Results and Business Update
November 05, 2020 07:30 ET
|
Adaptimmune Therapeutics plc
- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation...
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
August 28, 2020 10:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data...